Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

From consumer to healthcare, here's a list of key deals reported this week: Papa John's (NASDAQ:PZZA) jumped 18% on a report that a Qatari-backed investor is considering a takeover of the pizza chain.

On the political front, Robert F. Kennedy Jr. will become the next HHS secretary after he attained a majority of Senate votes ...

Blackstone (NYSE:BX) and Corsair Capital are looking to sell First Eagle Investment Management for more than $4B, the Financial Times reported late Friday, citing people briefed on the matter.

The heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes ...